New Animal Drugs; Change of Sponsor, 60551 [E7-21057]
Download as PDF
Federal Register / Vol. 72, No. 206 / Thursday, October 25, 2007 / Rules and Regulations
neither an environmental assessment
nor an environmental impact statement
is required.
This rule does not meet the definition
of ‘‘rule’’ in 5 U.S.C. 804(3)(A) because
it is a rule of ‘‘particular applicability.’’
Therefore, it is not subject to the
congressional review requirements in 5
U.S.C. 801–808.
List of Subjects in 21 CFR Part 520
Animal drugs.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs and redelegated to
the Center for Veterinary Medicine, 21
CFR part 520 is amended as follows:
I
PART 520—ORAL DOSAGE FORM
NEW ANIMAL DRUGS
change of sponsor for five approved new
animal drug applications (NADAs) from
Merial Ltd., to Huvepharma AD.
DATES: This rule is effective October 25,
2007.
FOR FURTHER INFORMATION CONTACT:
David R. Newkirk, Center for Veterinary
Medicine (HFV–100), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 301–827–6967, email: david.newkirk@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Merial
Ltd., 3239 Satellite Blvd., Bldg. 500,
Duluth, GA 30096–4640 has informed
FDA that it has transferred ownership
of, and all rights and interest in, the
following five approved NADAs to
Huvepharma AD, 33 James Boucher
Blvd., Sophia 1407, Bulgaria:
1. The authority citation for 21 CFR
part 520 continues to read as follows:
Application
No.
Authority: 21 U.S.C. 360b.
2. Add § 520.2130 to read as follows:
§ 520.2130
PART 520—ORAL DOSAGE FORM
NEW ANIMAL DRUGS
1. The authority citation for 21 CFR
part 520 continues to read as follows:
I
Authority: 21 U.S.C. 360b.
§ 520.100
[Amended]
2. In paragraph (b)(1) of § 520.100,
remove ‘‘050604’’ and in its place add
‘‘016592’’.
I
PART 558—NEW ANIMAL DRUGS FOR
USE IN ANIMAL FEEDS
3. The authority citation for 21 CFR
part 558 continues to read as follows:
I
Authority: 21 U.S.C. 360b, 371.
§ 558.55
[Amended]
4. In paragraph (a) of § 558.55, remove
‘‘050604’’ and in its place add ‘‘No.
016592’’.
I 5. In § 558.58, in the table in
paragraph (e)(1)(i), in the first entry, in
the ‘‘Sponsor’’ column, add ‘‘050604’’
and ‘‘016592’’; add paragraph (a)(3); and
revise paragraph (b) to read as follows:
I
I
I
60551
012–350
Spinosad.
(a) Specifications. Each chewable
tablet contains 140, 270, 560, 810, or
1620 milligrams (mg) spinosad.
(b) Sponsor. See No. 000986 in
§ 510.600 of this chapter.
(c) Conditions of use in dogs—(1)
Amount. Administer tablets once a
month at a recommended minimum
dosage of 13.5 mg per pound (30 mg per
kilogram) of body weight.
(2) Indications for use. To kill fleas
and for the prevention and treatment of
flea infestations (Ctenocephalides felis)
on dogs for 1 month.
(3) Limitations. Federal law restricts
this drug to use by or on the order of
a licensed veterinarian.
Dated: October 17, 2007.
Bernadette Dunham,
Deputy Director, Center for Veterinary
Medicine.
[FR Doc. E7–21058 Filed 10–24–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Trade name(s)
AMPROVINE (amprolium)
25% Type A Medicated
Article; CORID
(amprolium) 25% Type A
Medicated Article
013–149
AMPROVINE (amprolium)
9.6% Solution
013–461
Broiler PMX No. 1620
(amprolium/ethopabate)
033–165
AMPROVINE (amprolium)
20% Soluble Powder;
CORID (amprolium) 20%
Soluble Powder
034–393
COYDEN 25 (clopidol);
Lerbek 25
Accordingly, the agency is amending
the regulations in 21 CFR 520.100,
558.55, 558.58, and 558.175 to reflect
the transfer of ownership.
This rule does not meet the definition
of ‘‘rule’’ in 5 U.S.C. 804(3)(A) because
it is a rule of ‘‘particular applicability.’’
Therefore, it is not subject to the
congressional review requirements in 5
U.S.C. 801–808.
§ 558.58
Amprolium and ethopabate.
(a) * * *
(3) 25 percent amprolium and 0.8
percent ethopabate.
(b) Approvals. See § 510.600(c) of this
chapter.
(1) No. 050604 for products described
in paragraph (a) of this section.
(2) No. 016592 for product described
in paragraph (a)(3) of this section.
§ 558.175
[Amended]
6. In § 558.175, in paragraph (b) and
in the table in paragraph (d)(1) in the
‘‘Sponsor’’ column, remove ‘‘050604’’
and in its place add ‘‘016592’’.
I
Dated: October 17, 2007.
Bernadette Dunham,
Deputy Director, Center for Veterinary
Medicine.
[FR Doc. E7–21057 Filed 10–24–07; 8:45 am]
BILLING CODE 4160–01–S
List of Subjects
21 CFR Part 520
Food and Drug Administration
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Animal drugs.
21 CFR Parts 520 and 558
21 CFR Part 558
New Animal Drugs; Change of Sponsor
rwilkins on PROD1PC63 with RULES
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final rule.
The Food and Drug
Administration (FDA) is amending the
animal drug regulations to reflect a
SUMMARY:
VerDate Aug<31>2005
18:00 Oct 24, 2007
Jkt 214001
21 CFR Part 558
Animal drugs, Animal feeds.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs and redelegated to
the Center for Veterinary Medicine, 21
CFR parts 520 and 558 are amended as
follows:
New Animal Drugs For Use in Animal
Feeds; Change of Sponsor
I
PO 00000
Frm 00019
Fmt 4700
Sfmt 4700
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final rule.
SUMMARY: The Food and Drug
Administration (FDA) is amending the
E:\FR\FM\25OCR1.SGM
25OCR1
Agencies
[Federal Register Volume 72, Number 206 (Thursday, October 25, 2007)]
[Rules and Regulations]
[Page 60551]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-21057]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 520 and 558
New Animal Drugs; Change of Sponsor
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is amending the animal
drug regulations to reflect a change of sponsor for five approved new
animal drug applications (NADAs) from Merial Ltd., to Huvepharma AD.
DATES: This rule is effective October 25, 2007.
FOR FURTHER INFORMATION CONTACT: David R. Newkirk, Center for
Veterinary Medicine (HFV-100), Food and Drug Administration, 7500
Standish Pl., Rockville, MD 20855, 301-827-6967, e-mail:
david.newkirk@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Merial Ltd., 3239 Satellite Blvd., Bldg.
500, Duluth, GA 30096-4640 has informed FDA that it has transferred
ownership of, and all rights and interest in, the following five
approved NADAs to Huvepharma AD, 33 James Boucher Blvd., Sophia 1407,
Bulgaria:
------------------------------------------------------------------------
Application No. Trade name(s)
------------------------------------------------------------------------
012-350 AMPROVINE (amprolium) 25% Type A
Medicated Article; CORID (amprolium)
25% Type A Medicated Article
------------------------------------------------------------------------
013-149 AMPROVINE (amprolium) 9.6% Solution
------------------------------------------------------------------------
013-461 Broiler PMX No. 1620 (amprolium/
ethopabate)
------------------------------------------------------------------------
033-165 AMPROVINE (amprolium) 20% Soluble
Powder; CORID (amprolium) 20% Soluble
Powder
------------------------------------------------------------------------
034-393 COYDEN 25 (clopidol); Lerbek 25
------------------------------------------------------------------------
Accordingly, the agency is amending the regulations in 21 CFR
520.100, 558.55, 558.58, and 558.175 to reflect the transfer of
ownership.
This rule does not meet the definition of ``rule'' in 5 U.S.C.
804(3)(A) because it is a rule of ``particular applicability.''
Therefore, it is not subject to the congressional review requirements
in 5 U.S.C. 801-808.
List of Subjects
21 CFR Part 520
Animal drugs.
21 CFR Part 558
Animal drugs, Animal feeds.
0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs and
redelegated to the Center for Veterinary Medicine, 21 CFR parts 520 and
558 are amended as follows:
PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS
0
1. The authority citation for 21 CFR part 520 continues to read as
follows:
Authority: 21 U.S.C. 360b.
Sec. 520.100 [Amended]
0
2. In paragraph (b)(1) of Sec. 520.100, remove ``050604'' and in its
place add ``016592''.
PART 558--NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
0
3. The authority citation for 21 CFR part 558 continues to read as
follows:
Authority: 21 U.S.C. 360b, 371.
Sec. 558.55 [Amended]
0
4. In paragraph (a) of Sec. 558.55, remove ``050604'' and in its place
add ``No. 016592''.
0
5. In Sec. 558.58, in the table in paragraph (e)(1)(i), in the first
entry, in the ``Sponsor'' column, add ``050604'' and ``016592''; add
paragraph (a)(3); and revise paragraph (b) to read as follows:
Sec. 558.58 Amprolium and ethopabate.
(a) * * *
(3) 25 percent amprolium and 0.8 percent ethopabate.
(b) Approvals. See Sec. 510.600(c) of this chapter.
(1) No. 050604 for products described in paragraph (a) of this
section.
(2) No. 016592 for product described in paragraph (a)(3) of this
section.
Sec. 558.175 [Amended]
0
6. In Sec. 558.175, in paragraph (b) and in the table in paragraph
(d)(1) in the ``Sponsor'' column, remove ``050604'' and in its place
add ``016592''.
Dated: October 17, 2007.
Bernadette Dunham,
Deputy Director, Center for Veterinary Medicine.
[FR Doc. E7-21057 Filed 10-24-07; 8:45 am]
BILLING CODE 4160-01-S